You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Potassium phosphate, dibasic; potassium phosphate, monobasic - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for potassium phosphate, dibasic; potassium phosphate, monobasic and what is the scope of freedom to operate?

Potassium phosphate, dibasic; potassium phosphate, monobasic is the generic ingredient in two branded drugs marketed by Am Regent, Amneal, Cmp Dev Llc, Fresenius Kabi Usa, and Somerset Theraps Llc, and is included in six NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Potassium phosphate, dibasic; potassium phosphate, monobasic has one patent family member in one country.

Six suppliers are listed for this compound.

Summary for potassium phosphate, dibasic; potassium phosphate, monobasic
International Patents:1
US Patents:1
Tradenames:2
Applicants:5
NDAs:6
Finished Product Suppliers / Packagers: 6
DailyMed Link:potassium phosphate, dibasic; potassium phosphate, monobasic at DailyMed
Pharmacology for potassium phosphate, dibasic; potassium phosphate, monobasic

US Patents and Regulatory Information for potassium phosphate, dibasic; potassium phosphate, monobasic

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fresenius Kabi Usa POTASSIUM PHOSPHATES potassium phosphate, dibasic; potassium phosphate, monobasic SOLUTION;INTRAVENOUS 212832-003 Nov 26, 2019 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fresenius Kabi Usa POTASSIUM PHOSPHATES potassium phosphate, dibasic; potassium phosphate, monobasic SOLUTION;INTRAVENOUS 212832-002 Nov 26, 2019 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Amneal POTASSIUM PHOSPHATES potassium phosphate, dibasic; potassium phosphate, monobasic SOLUTION;INTRAVENOUS 216344-003 Oct 10, 2023 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Fresenius Kabi Usa POTASSIUM PHOSPHATES potassium phosphate, dibasic; potassium phosphate, monobasic SOLUTION;INTRAVENOUS 212832-001 Nov 26, 2019 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Am Regent POTASSIUM PHOSPHATES potassium phosphate, dibasic; potassium phosphate, monobasic SOLUTION;INTRAVENOUS 216274-002 Oct 2, 2023 AP RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for potassium phosphate, dibasic; potassium phosphate, monobasic

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2020081118 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for potassium phosphate, dibasic; potassium phosphate, monobasic

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1441735 2008/010 Ireland ⤷  Sign Up PRODUCT NAME: RALTEGRAVIR OR A PHARMECEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; NAT AUTHORISTION NO/DATE: EU/1/07/436/001-002 20071220;
1499331 SPC/GB13/034 United Kingdom ⤷  Sign Up PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313
0480717 98C0025 Belgium ⤷  Sign Up PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
1718641 2012/008 Ireland ⤷  Sign Up PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
0733366 SPC/GB98/031 United Kingdom ⤷  Sign Up PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.